NCT07055399 - Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 21, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2029

Conditions

Locally Advanced Cervical Cancer

Interventions

DRUG

neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimab and tuvonralimab for 2 cycles

"Neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab, cisplatin, and nab-paclitaxel for 1 cycle, then Iparomlimab and tuvonralimab continued for 2 cycles at 3-week intervals. Details:~Iparomlimab and tuvonralimab 5 mg/kg, IV infusion, Q3W for 3 cycles Cisplatin：75-80 mg/m2, IV infusion, (cycle 1) Nab-paclitaxel 260 mg/m2，30min，IV infusion,(cycle 1)"

Trial Locations (1)

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors

collaborator

Jiangsu Cancer Institute & Hospital

OTHER

collaborator

Fuzhou University Affiliated Provincial Hospital

OTHER

collaborator

First Affiliated Hospital of Fujian Medical University

OTHER

lead

Fujian Cancer Hospital

OTHER_GOV